Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort
dc.creator | Papatheodoridis, G. V. | en |
dc.creator | Manolakopoulos, S. | en |
dc.creator | Touloumi, G. | en |
dc.creator | Nikolopoulou, G. | en |
dc.creator | Raptopoulou-Gigi, M. | en |
dc.creator | Gogos, C. | en |
dc.creator | Vafiadis-Zouboulis, I. | en |
dc.creator | Karamanolis, D. | en |
dc.creator | Chouta, A. | en |
dc.creator | Ilias, A. | en |
dc.creator | Drakoulis, C. | en |
dc.creator | Mimidis, K. | en |
dc.creator | Ketikoglou, I. | en |
dc.creator | Manesis, E. | en |
dc.creator | Mela, M. | en |
dc.creator | Hatzis, G. | en |
dc.creator | Dalekos, G. N. | en |
dc.date.accessioned | 2015-11-23T10:44:29Z | |
dc.date.available | 2015-11-23T10:44:29Z | |
dc.date.issued | 2015 | |
dc.identifier | 10.1111/jvh.12283 | |
dc.identifier.issn | 13520504 | |
dc.identifier.uri | http://hdl.handle.net/11615/31950 | |
dc.description.abstract | Hepatocellular carcinoma (HCC) may still develop in chronic hepatitis B (CHB) patients treated with lamivudine. Whether HCC rates are comparable in patients treated with the current first-line antivirals remains uncertain. We estimated the incidence and evaluated predictors of HCC in a large nationwide prospective cohort (HepNet.Greece) of HBeAg-negative CHB patients treated with entecavir. HBeAg-negative CHB patients from the same cohort who were initially treated with lamivudine were used as controls. We included 321 patients treated with entecavir for a median of 40 months and 818 patients treated initially with lamivudine for a median of 60 months. In the entecavir group, HCC developed in 4 of 321 (1.2%) patients at a median of 1.5 (range: 1.0-4.5) years, while the cumulative HCC incidence was significantly higher in cirrhotics than noncirrhotics (1, 3, 5 years: 0%, 3%, 9% vs 1%, 1%, 1%; P = 0.024) and in older patients (P = 0.026). Entecavir compared with lamivudine group patients had lower HCC incidence (1, 3, 5 years: 0.3%, 1.2%, 2.8% vs 0.7%, 3.8%, 5.6%; P = 0.024). However, in multivariable Cox regression analysis, the HCC risk was independently associated with older age (P < 0.001), male gender (P = 0.011) and cirrhosis (P = 0.025), but not with the initial agent. In conclusion, our large nationwide study indicates that the HCC risk remains increased in entecavir-treated HBeAg-negative CHB patients with cirrhosis, particularly of older age, at least for the first 5 years. The HCC risk does not seem to be significantly reduced with entecavir compared with antiviral therapy starting with lamivudine. © 2014 John Wiley & Sons Ltd. | en |
dc.source.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-84921439595&partnerID=40&md5=c3bff022ba497c0e9eb17c833c9bf5bd | |
dc.subject | Cirrhosis | en |
dc.subject | entecavir | en |
dc.subject | hepatitis B | en |
dc.subject | hepatocellular carcinoma | en |
dc.subject | lamivudine | en |
dc.subject | adefovir | en |
dc.subject | alanine aminotransferase | en |
dc.subject | alpha fetoprotein | en |
dc.subject | hepatitis B(e) antigen | en |
dc.subject | peginterferon alpha | en |
dc.subject | tenofovir | en |
dc.subject | virus DNA | en |
dc.subject | adult | en |
dc.subject | antiviral therapy | en |
dc.subject | Article | en |
dc.subject | cancer risk | en |
dc.subject | controlled study | en |
dc.subject | decompensated liver cirrhosis | en |
dc.subject | female | en |
dc.subject | follow up | en |
dc.subject | human | en |
dc.subject | liver cell carcinoma | en |
dc.subject | liver cirrhosis | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | priority journal | en |
dc.subject | prospective study | en |
dc.subject | treatment duration | en |
dc.title | Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort | en |
dc.type | journalArticle | en |
Αρχεία σε αυτό το τεκμήριο
Αρχεία | Μέγεθος | Τύπος | Προβολή |
---|---|---|---|
Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο. |